Definition
Selective serotonin reuptake inhibitors, or SSRIs, are a class of medication that increase the availability of serotonin in the synapse by blocking its reuptake. Medications in this class include sertraline, escitalopram, fluoxetine, citalopram, and paroxetine. They're considered first-line pharmacologic treatment for most anxiety disorders.
What they can feel like
Patients rarely describe SSRIs as feeling medicated. The more common description is that the same things that used to provoke anxiety still happen, and they bother the person less. The grip of worry softens. Sleep often improves. The body feels less braced. Early on, side effects can include nausea, jitteriness, mild headaches, and changes in sleep. Most settle within two weeks.
How they work
The immediate effect is biochemical: more serotonin in the synapse. The clinical effect develops over weeks. Current understanding is that sustained serotonergic signaling produces gradual changes in how regions of the brain involved in threat detection respond to potential danger. The reactivity comes down. The baseline becomes quieter.
Mechanism in brief
SSRIs (selective serotonin reuptake inhibitors) block the reuptake transporter that pulls serotonin back into the presynaptic neuron after release, which increases the amount of serotonin in the synapse. The clinical effect on anxiety and depression develops over four to six weeks because it depends on downstream changes in receptor sensitivity, gene expression, and neuroplasticity rather than the immediate change in serotonin levels. This is why patients shouldn't expect a noticeable improvement in the first week, and why a fair trial requires staying at an adequate dose for at least six weeks.
Specific agents and what they're usually chosen for
Six SSRIs see most clinical use, and each has a clinical profile worth knowing in brief. Sertraline is a common first choice because of a favorable side effect profile, a wide dose range, and good evidence across anxiety, depression, OCD, and PTSD. Escitalopram is also commonly first-line, with a clean side effect profile and predictable dosing. Fluoxetine has a long half-life that makes missed doses more forgiving and discontinuation gentler; it's the SSRI with the most evidence in adolescents. Paroxetine is effective but has a shorter half-life that produces noticeable discontinuation symptoms, and is generally avoided in pregnancy. Citalopram is effective and inexpensive but carries a dose ceiling because of QT-interval effects at higher doses. Fluvoxamine sees most use in OCD specifically.
The choice among them is individual. First trial usually goes well, and there's no clinical rule about which to start with, prescriber experience, prior family response, side effect profile, drug interactions, and cost all factor in.
Common side effects in the first weeks
The most common reasons patients stop an SSRI in the first two weeks are nausea, headache, and sleep disruption. These are typically transient and resolve within two to three weeks. Taking the dose with food, splitting morning and evening dosing, and starting at a lower dose with a gradual ramp usually addresses the early period.
Sexual side effects, reduced libido, delayed orgasm, erectile difficulty, occur in a meaningful minority of patients and are often the reason for considering a switch later in treatment. They're usually dose-related and often improve with dose adjustment or with a switch to a different SSRI or to bupropion.
Weight changes are usually modest. Some SSRIs (paroxetine in particular) are associated with weight gain over time; others are weight-neutral.
Why the trial needs to be long enough at a high enough dose
A common reason patients conclude an SSRI didn't work is that the trial was too short or the dose too low. Clinical effect on anxiety and depression typically develops over four to six weeks at a therapeutic dose; OCD often takes 8 to 12 weeks at higher doses (often two to three times the dose used for depression). A four-week trial at a starting dose isn't an adequate trial. Before concluding an SSRI isn't working, the prescriber will usually escalate to a full therapeutic dose and continue for at least six weeks.
If a first SSRI doesn't produce enough response after an adequate trial, switching to a second SSRI is the most common next step. About half of patients who don't respond to the first SSRI will respond to the second. After two adequate SSRI trials, an SNRI or augmentation strategy is usually considered.
When to see a clinician
Anyone considering an SSRI is best served by a prescriber familiar with the full set of options and with experience matching agent to patient. The first SSRI tried is the right one for most patients; for those who don't respond, a second SSRI or an SNRI is usually the next step.